Oculis Holding AG (NASDAQ:OCS) Sees Significant Drop in Short Interest

Oculis Holding AG (NASDAQ:OCS) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 15,700 shares, a decline of 65.2% from the October 15th total of 45,100 shares. Based on an average daily volume of 47,400 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company’s shares are short sold.

Oculis Stock Performance

Oculis stock traded down $1.00 during midday trading on Tuesday, reaching $14.99. 97,634 shares of the company’s stock were exchanged, compared to its average volume of 36,858. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.27 and a current ratio of 5.27. The firm has a market cap of $607.15 million, a price-to-earnings ratio of -8.28 and a beta of -0.16. The stock’s 50-day simple moving average is $14.09 and its 200 day simple moving average is $12.64. Oculis has a 52 week low of $9.60 and a 52 week high of $18.00.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 71.90% and a negative net margin of 8,043.28%. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. On average, analysts expect that Oculis will post -2.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Oculis in a research note on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $29.20.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.